Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, on 4 February 2021 announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million.
In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. This over-allotment option was exercised on 5 February 2021 in full. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on 8 February 2021 under the symbol "PHVS."
Morgan Stanley, BofA Securities, and SVB Leerink act as joint book-running managers in connection with the IPO of Pharvaris on NASDAQ
Loyens & Loeff N.V. acted as Dutch counsel for Morgan Stanley, BofA Securities, and SVB Leerink, acting as joint book-running managers for the offering. Oppenheimer & Co. and Kempen & Co acted as co-managers.
